Loading clinical trials...
Loading clinical trials...
FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 2 Preceded by Dose Finding in Phase 1
Conditions
Interventions
Bemarituzumab
Modified FOLFOX6
Locations
7
United States
The University of Arizona Cancer Center
Tucson, Arizona, United States
Marin Cancer Care
Greenbrae, California, United States
Innovative Clinical Research Institute
Whittier, California, United States
The University of Chicago Medical Center
Chicago, Illinois, United States
Karmanos Cancer Institute
Detroit, Michigan, United States
Wilmont Cancer Institute
Rochester, New York, United States
Start Date
November 30, 2017
Primary Completion Date
January 31, 2019
Completion Date
January 31, 2019
Last Updated
February 28, 2024
NCT04704661
NCT04550494
NCT05489211
NCT04674267
NCT05702229
NCT07217704
Lead Sponsor
Five Prime Therapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions